Kenvue Inc. (KVUE) Financial Statements
Historical financial data — 13 statements covering FY2023–FY2025
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and...
Kenvue Inc.'s revenue decreased 2.1% year over year, from $15.46B to $15.12B.
Net income increased 42.7% over the same period, from $1.03B to $1.47B.
Total debt decreased by 6.4% to $1.45B.
The debt-to-equity ratio stands at 0.13, indicating a conservative leverage profile.
Operating cash flow grew 24.2% to $2.20B.
Kenvue Inc. maintains a moderate net profit margin of 9.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $11.78B+49.8% | $1.34B | $6.60B | $2.05B | $2.22B | $27.08B | $7.68B | $10.89B |
| Q1 FY2024 | $3.89B-66.9% | $296.0M | $2.24B | $550.0M | $287.0M | $27.28B | $1.52B | $10.62B |
| Q2 FY2024 | $7.89B+102.7% | $354.0M | $4.61B | $704.0M | $727.0M | $26.44B | $1.43B | $10.18B |
| Q3 FY2024 | $11.79B+49.4% | $737.0M | $6.89B | $1.36B | $976.0M | $26.93B | $1.65B | $10.64B |
| Q1 FY2025 | $3.74B-68.3% | $322.0M | $2.17B | $558.0M | $428.0M | $26.26B | $2.43B | $10.05B |
| Q2 FY2025 | $7.58B+102.6% | $742.0M | $4.43B | $1.25B | $1.05B | $27.13B | $1.55B | $10.73B |
| Q3 FY2025 | $11.34B+49.7% | $1.14B | $6.66B | $1.88B | $1.34B | $27.25B | $1.91B | $10.63B |
| Q1 FY2026 | $3.91B-65.5% | $474.0M | $2.30B | $767.0M | $489.0M | $26.85B | $1.59B | $10.61B |
Balance Sheet Summary (Latest Period)
Total Assets
$27.08B
Total Liabilities
$16.31B
Total Equity
$10.77B
Cash & Equivalents
$1.06B
Total Debt
$1.45B
Current Assets
$5.70B
Current Liabilities
$5.95B
Retained Earnings
$-204.0M